Processa Pharmaceuticals Inc. has announced that it received a notification from the Nasdaq Stock Market regarding its failure to meet the minimum bid price requirement of $1.00 per share for its common stock. The company has been granted a second 180-day grace period, ending on February 2, 2026, to regain compliance. Processa Pharmaceuticals is considering a reverse stock split as a potential solution to meet the requirement. During this period, the company's stock will continue to be listed and traded on the Nasdaq Capital Market, as long as it meets other listing standards.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.